VIRIDIAN THERAPEUTICS INC's ticker is VRDN and the CUSIP is 92790C104. A total of 59 filers reported holding VIRIDIAN THERAPEUTICS INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $37,681,500 | -57.2% | 2,896,349 | -42.4% | 1.44% | -53.5% |
| Q1 2024 | $88,100,164 | -15.6% | 5,031,420 | +4.9% | 3.10% | -36.6% |
| Q4 2023 | $104,423,949 | +84.9% | 4,794,488 | +30.2% | 4.89% | +27.6% |
| Q3 2023 | $56,477,999 | -1.7% | 3,681,747 | +52.4% | 3.83% | -13.7% |
| Q2 2023 | $57,458,940 | +8.3% | 2,415,256 | +15.8% | 4.44% | -11.7% |
| Q1 2023 | $53,060,157 | +3.7% | 2,085,698 | +19.1% | 5.03% | -16.2% |
| Q4 2022 | $51,151,588 | +52.4% | 1,751,167 | +7.0% | 6.00% | +34.2% |
| Q3 2022 | $33,559,000 | +122.0% | 1,636,211 | +25.2% | 4.47% | +48.4% |
| Q2 2022 | $15,117,000 | -34.9% | 1,306,569 | +4.0% | 3.01% | -50.9% |
| Q1 2022 | $23,224,000 | -2.8% | 1,256,051 | +3.9% | 6.14% | -10.0% |
| Q4 2021 | $23,903,000 | – | 1,209,051 | – | 6.83% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TCG Crossover Management, LLC | 1,314,000 | $15,203,000 | 6.46% |
| Ally Bridge Group (NY) LLC | 496,012 | $5,739,000 | 5.23% |
| VR Adviser, LLC | 1,852,919 | $21,438,000 | 4.22% |
| COMMODORE CAPITAL LP | 1,638,609 | $18,959,000 | 4.01% |
| Ghost Tree Capital, LLC | 600,000 | $6,942,000 | 3.62% |
| Paradigm Biocapital Advisors LP | 1,306,569 | $15,117,000 | 3.01% |
| Fairmount Funds Management LLC | 944,092 | $10,923,000 | 2.50% |
| Kynam Capital Management, LP | 590,143 | $6,828,000 | 1.74% |
| Soleus Capital Management, L.P. | 841,018 | $9,731,000 | 1.52% |
| Vivo Capital, LLC | 1,300,000 | $15,041,000 | 1.51% |